Q-omics provides the consensus-scored MSH5-SAPCD1 profile across patient tissues and cancer cell-line models. MSH5-SAPCD1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MSH5-SAPCD1 is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, MSH5-SAPCD1 RNA expression shows 16,982 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, KICH, and UVM as cancer lineages where MSH5-SAPCD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MSH5-SAPCD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MSH5-SAPCD1 survival associations across molecular data types. MSH5-SAPCD1 RNA expression shows survival associations in the most cancer types (26). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MSH5-SAPCD1 RNA expression–survival associations across cancer types. High MSH5-SAPCD1 expression shows unfavorable associations in KIRC, ACC and LGG, but favorable associations in HNSC, READ and BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MSH5-SAPCD1 RNA expression.
This table summarizes MSH5-SAPCD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for MSH5-SAPCD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MSH5-SAPCD1 shows lower tumor expression in KICH and KIRC and higher tumor expression in LIHC, BLCA, STAD and THCA. The KICH box plot shows higher MSH5-SAPCD1 RNA expression in normal versus tumor tissue (log2 FC = −0.529, t-test p < 0.001).
This table shows molecular features associated with MSH5-SAPCD1 in patient tissues and cancer cell lines. In patient samples, MSH5-SAPCD1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, MSH5-SAPCD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS.
